[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31841":3,"doc-seo-31841":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},31841,687197207639,"Asher","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",8,"Research & Report","Serum Alpha and Beta-CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies","Objective: To analyze how circulating alpha and beta-CGRP levels change during CGRP monoclonal antibody treatment in chronic migraine patients. Methods: Sex- and age-paired healthy controls were recruited; blood was collected in free-migraine periods before treatment, 2 weeks after the first dose, and 3 months after, with isoform-specific ELISAs measuring alpha- and beta-CGRP. Results: Alpha-CGRP increased at baseline and progressively normalized with treatment, correlating with efficacy; beta-CGRP remained unchanged and unmodulated. Interpretation: Normalization of alpha-CGRP supports its role as a first chronic migraine biomarker.","cbCaihH5CMKhCk7L","https://ap.wps.com/l/cbCaihH5CMKhCk7L","pdf",3193611,1,26,"English","en","# Abstract\n## Objective\n## Methods\n## Results\n## Interpretation\n# Introduction","[{\"question\":\"What is the primary objective of the study?\",\"answer\":\"To analyze the evolution of alpha and beta-CGRP circulating levels during CGRP monoclonal antibody treatment in chronic migraine patients.\"},{\"question\":\"How were patients and controls enrolled and when were blood samples collected?\",\"answer\":\"Chronic migraine patients starting monoclonal antibody therapy were recruited alongside sex- and age-paired healthy controls. Blood was taken before treatment, two weeks after the first dose, and three months after, always during free-migraine periods.\"},{\"question\":\"What were the main findings regarding alpha- and beta-CGRP?\",\"answer\":\"Alpha-CGRP was elevated at baseline and progressively decreased during treatment, correlating with clinical response. Beta-CGRP did not differ at baseline and was not modulated by treatment.\"}]",1780261359,66,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"serum-alpha-and-beta-cgrp-levels-in-chronic-migraine-patients-before-and-after-monoclonal-antibodies","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/research-report/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/serum-alpha-and-beta-cgrp-levels-in-chronic-migraine-patients-before-and-after-monoclonal-antibodies/31841/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-05-31",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"What is the primary objective of the study?","Question",{"text":73,"@type":74},"To analyze the evolution of alpha and beta-CGRP circulating levels during CGRP monoclonal antibody treatment in chronic migraine patients.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"How were patients and controls enrolled and when were blood samples collected?",{"text":78,"@type":74},"Chronic migraine patients starting monoclonal antibody therapy were recruited alongside sex- and age-paired healthy controls. Blood was taken before treatment, two weeks after the first dose, and three months after, always during free-migraine periods.",{"name":80,"@type":71,"acceptedAnswer":81},"What were the main findings regarding alpha- and beta-CGRP?",{"text":82,"@type":74},"Alpha-CGRP was elevated at baseline and progressively decreased during treatment, correlating with clinical response. Beta-CGRP did not differ at baseline and was not modulated by treatment.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]